Pharmafile Logo
Pharmafocus logo
Advanced Search

opdivo

Showing 15 posts of 107 posts found.

acute_lymphoblastic_leukaemia_smear

Azacitidine and nivolumab combo proves successful in phase II trial

November 13, 2018
Manufacturing and Production Cancer, leukaemia, opdivo, pharma, texas

A combination of chemotherapy drug azacitidine and nivolumab (Bristol-Myers Squibb’s Opdivo) has proven effective in treating patients with relapsed or …

News

BMS’ Opdivo and Yervoy combination shows outstanding survival rate in cancer patients

October 22, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Yervoy, melanoma, opdivo

American pharma firm Bristol-Myers Squibb have announced that more than 53% of patients with advanced melanoma, who were treated with …

News
opdivo_1_1

BMS’ Opdivo fails to win over NICE as adjuvant melanoma therapy

September 10, 2018
Sales and Marketing BMS, NHS, NICE, melanoma, opdivo, pharma

Bristol-Myers Squibb has failed to convince NICE to approve the use of its PD-1 inhibitor immunotherapy Opdivo (nivolumab) as an …

News
Image Credit: Bristol-Myers Squibb

FDA approves Bristol Myers Squibb’s Opdivo in small-cell lung cancer

August 20, 2018
Sales and Marketing Bristol-Myers Squibb, FDA, approval, bristol myers squibb, lung cancer, opdivo

The FDA has approved Bristol Myers Squibb’s Opdivo (nivolumab) for patients with metastatic small-cell lung cancer (SCLC), as the first …

News
opdivo_1_1

NICE turns down BMS’ blockbuster Opdivo for urothelial carcinoma

July 5, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, NICE, opdivo, pharma, urothelial carcinoma

Just in time for the NHS’ 70th birthday, UK watchdog NICE has announced that it has taken the decision to …

News
pharmafocus_july-august_2018_cover

The July/August issue of Pharmafocus is now live!

July 4, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Elizabeth Holmes, NHS, Sanofi, Theranos, UK, ambien, manufacturing compliance, opdivo, patient recruitment, patient retention, pharma

The new July/August edition of Pharmafocus is now available to read online.

News
opdivo_1_1

BMS’ Opdivo becomes first immuno-oncology agent available in China

June 18, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, China, NSCLC, lung cancer, oncology, opdivo, pharma

Bristol-Myers Squibb’s flagship immunotherapy Opdivo (nivolumab) has broken ground to become the first and only PD-1 inhibitor to be made …

News

BMS pulls the plug on Phase 3 trials of IDO1 inhibitor

May 2, 2018
Research and Development BMS, Bristol-Myers Squibb, IDO1, opdivo, pharma, phase 3

Bristol-Myers Squibb has terminated two pivotal Phase 3 trials of BMS-986205, an IDO1 inhibitor acquired through its $800 million acquisition …

News
pharmafocus_may_2018_cover

The May 2018 issue of Pharmafocus is now live!

April 23, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, MSD, Pharmafocus, Shire, Takeda, flypharma, keytruda, mhealth, mobile health summit, opdivo, pharma, sugar tax

Just in time for the first good weather of the year, the May 2018 edition of Pharmafocus is available to …

News

BMS’ Opdivo+Yervoy combo secures FDA approval in kidney cancer

April 18, 2018
Research and Development, Sales and Marketing BMS, Bristol Myers Swuibb, Cancer, FDA, Yervoy, carcinoma, opdivo, pharma

The FDA has announced its approval of a combination of Opdivo (nivolumab) and Yervoy (ipilimumab), both products from Bristol Myers …

News
japan-112722_640

Japan saves record $12.2bn in 2017 through greater generic use

March 7, 2018
Research and Development, Sales and Marketing Japan, generics, keytruda, opdivo, pharma

Through a concerted shift from branded drugs to generic equivalents as a means to lower prescription costs, Japan is estimated …

News

BMS’ Opdivo and Yervoy combo better than chemo in halting lung cancer progression

February 6, 2018
Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, NSCLC, Yervoy, lung cancer, opdivo, pharma

Bristol-Myers Squibb has revealed promising data from its ongoing Phase 3 study investigating the efficacy of Opdivo (nivolumab) in combination …

News

BMS partners again with the company behind Opdivo

December 14, 2017
Medical Communications, Sales and Marketing Bristol-Myers Squibb, biotech, drugs, opdivo, pharma, pharmaceutical

Bristol-Myers Squibb has once again struck a deal with Ono Pharmaceutical for multiple programs, seeking to discover a boost to …

News
humacao_exterior

BMS agrees deal on Opdivo availability through Cancer Drugs Fund for head and neck cancer

October 13, 2017
Sales and Marketing BMS, Bristol-Myers Squibb, CDF, Cancer Drugs Fund, NICE, opdivo, pharma, pharmaceutical

Thanks to successful negotiation of a managed access agreement, NICE has announced its recommendation of Bristol-Myers Squibb’s Opdivo (nivolumab) for …

News

BMS’ Opdivo to finally be made available to lung cancer patients in the UK

September 20, 2017
Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, biotech, drugs, opdivo, pharma, pharmaceutical

It is two and a half years since patients with lung cancer in the US were able to receive Bristol-Myers …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023